Litcius/Paper detail

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Hao Lei, San‐Qi Zhang, Shu Fan, Huanrong Bai, Hongyi Zhao, Shuai Mao, Minhang Xin

2021Journal of Medicinal Chemistry26 citationsDOIOpen Access PDF

Abstract

Mixed lineage leukemia (MLL) gene rearrangements are associated with acute leukemia. The protein menin is regarded as a critical oncogenic cofactor of the resulting MLL fusion proteins in acute leukemia. A direct interaction between menin and the MLL amino terminal sequences is necessary for MLL fusion protein-mediated leukemogenesis. Thus, inhibition of the interaction between menin and MLL has emerged as a novel therapeutic strategy. Recent improvements in structural biology and chemical reactivity have promoted the design and development of selective and potent menin-MLL interaction inhibitors. In this Perspective, different classes of menin-MLL interaction inhibitors are comprehensively summarized. Further research potential, challenges, and opportunities in the field are also discussed.

Topics & Concepts

ChemistryLeukemiaFusion proteinCancer researchSmall moleculeProtein–protein interactionFusion geneComputational biologyGeneBiochemistryGeneticsBiologyRecombinant DNAProtein Degradation and InhibitorsAdvanced biosensing and bioanalysis techniquesClick Chemistry and Applications
Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia | Litcius